SillaJen Biotherapeutics, Inc.

24 articles with SillaJen Biotherapeutics, Inc.

• SillaJen Announces Conclusions From Interim Futility Analysis Of Phase 3 PHOCUS Trial in HCC

  8/2/2019

  SillaJen, Inc., (KOSDAQ:215600), today announced that the Independent Data Monitoring Committee (IDMC) for the company's PHOCUS trial has evaluated the results of a formal pre-planned futility analysis for this study, and has recommended discontinuation of the trial. The PHOCUS trial is a Phase 3

• SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer

  9/4/2018

  The PHOCUS trial is designed to enroll 600 patients, worldwide, who have not received prior systemic treatment for their cancer

• Transgene to Present New Clinical Data on Oncolytic Virus Pexa-Vec at ASCO 2018

  5/17/2018

  TRANSGENE (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases, announces that new clinical data on the oncolytic virus Pexa-Vec will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 1 to 5 June in Chicago.

• SillaJen Poster Presentation at 2018 GU ASCO Symposium Highlights New Clinical Data in RCC, Intravenous Delivery of Pexa-Vec, Oncolytic Immunotherapy

  2/23/2018

  SillaJen Inc. presented new renal cell carcinoma clinical data at the American Society of Clinical Oncology Genitourinary Cancers Symposium last week in San Francisco, CA.

• SillaJen Announces First Patient Enrolled in the NCI-Sponsored Trial Evaluating Combination Therapy in Colorectal Cancer with SillaJen's Pexa-Vec Oncolytic Immunotherapy

  1/29/2018

  Under the CRADA, SillaJen will collaborate with Dr. Greten to evaluate the combination of SillaJen's lead clinical candidate, Pexa-Vec in combination with durvaluma.

• SillaJen and ABL Europe Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies

  1/23/2018

  Under the current agreement, ABL is currently manufacturing Pexa-Vec for SillaJen's multinational, randomized Phase 3, open-label study of Pexa-Vec in patients with advanced liver cancer.

• SillaJen Announces Collaboration With The NCI For Development Of Combination Therapy With SillaJen's Pexastimogene Devacirepvec (Pexa-Vec) Oncolytic Immunotherapy

  8/17/2017

• SillaJen And Lee's Pharmaceutical Announce Approval By The China CFDA To Commence Phase III Clinical Trial For Oncolytic Immunotherapy, Pexa-Vec, In Liver Cancer

  7/21/2017

• Regeneron And SillaJen Announce Immuno-Oncology Clinical Study Agreement For Combination Treatment In Kidney Cancer

  5/8/2017

• SillaJen And TRANSGENE Announce The Enrollment Of The First European Patient In Multinational Phase III Trial For Pexa-Vec In Advanced Liver Cancer

  4/25/2017

• SillaJen And TRANSGENE Announce The Enrollment Of The First European Patient In Multinational Phase III Trial For Pexa-Vec In Advanced Liver Cancer

  4/24/2017

• ASCO2016: SillaJen Announces Poster Presentation At ASCO Annual Meeting

  5/31/2016

• SillaJen Announces Commercial Manufacturing Agreement With ABL Europe For Lead Oncolytic Virus, Pexa-Vec

  5/16/2016

• SillaJen Enrolls First U.S. Patient In Multinational Phase 3 Trial For Pexa-Vec In Advanced Liver Cancer

  3/29/2016

• Medivate Partners Invests $12 Million In SillaJen

  3/21/2016

• SillaJen Announces First Patient Randomized In Multinational Phase 3 Trial For Pexa-Vec In Advanced Liver Cancer

  1/6/2016

• TRANSGENE And SillaJen Announce Revised Agreement For Pexa-Vec Oncolytic Viral Therapy And Provide Update On Clinical Development

  11/12/2015

• SillaJen Publishes Clinical Data Demonstrating Safe Administration Of Multiple Intravenous Doses Of Oncolytic Virus In Patients With Metastatic Colorectal Cancer

  6/29/2015

• SillaJen Presents Data Demonstrating Pexa-Vec Synergy With Angiogenesis Inhibitors: A Collaboration With University of California, San Francisco (UCSF)

  4/20/2015

• SillaJen Announces Agreement With The FDA For A Special Protocol Assessment For Upcoming Phase 3 Pexa-Vec Trial In Advanced Liver Cancer

  4/16/2015